In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Incyte (INCY – Research Report). The company’s shares closed yesterday at $51.65.
Devarakonda covers the Healthcare sector, focusing on stocks such as Cytokinetics, Keros Therapeutics, and Incyte. According to TipRanks, Devarakonda has an average return of 16.4% and a 47.76% success rate on recommended stocks.
In addition to Truist Financial, Incyte also received a Buy from Piper Sandler’s Allison Bratzel in a report issued yesterday. However, today, JMP Securities reiterated a Hold rating on Incyte (NASDAQ: INCY).
Based on Incyte’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.01 billion and a net profit of $201.08 million. In comparison, last year the company earned a revenue of $926.7 million and had a net profit of $28.46 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incyte (INCY) Company Description:
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Read More on INCY:
- Incyte initiated with a Neutral at Cantor on ‘lukewarm view’ of pipeline
- Incyte initiated with a Neutral at Cantor Fitzgerald
- Incyte gets payment from CMS Skinhealth for povorcitinib commercialization
- Incyte, CMS enter collaboration, license agreement for povorcitinib in China
- Incyte participates in a conference call with JPMorgan
